Product
Fluconazole
Aliases
Diflucan, Fluconazole 150 mg, Fluconazole 400 mg, Fluconazole (AxMP)
Name
Fluconazole
INN Name
fluconazole
FDA Approved
Yes
27 clinical trials
5 organizations
38 indications
2 documents
Indication
HealthyIndication
LymphomaIndication
Drug InteractionsIndication
Diffuse Large B-Cell LymphomaIndication
Primary Mediastinal LymphomaIndication
mantle cell lymphomaIndication
Advanced Solid TumorIndication
Marginal Zone LymphomaIndication
Vulvovaginal CandidiasisIndication
Vaginal CandidiasisIndication
CandidemiaIndication
MycosisIndication
Fungal InfectionIndication
invasive candidiasisIndication
Recurrent Vulvovaginal CandidiasisIndication
Malignant TumorIndication
bioequivalenceIndication
CandidiasisIndication
InvasiveIndication
B-cell LymphomaIndication
Acute Myeloid LeukemiaIndication
Genetic PredispositionIndication
AspergillosisIndication
Crohn's diseaseIndication
Inflammatory Bowel DiseaseIndication
VulvovaginalIndication
Kidney stonesIndication
NephrocalcinosisIndication
HypercalciuriaIndication
Fungal sepsisIndication
Invasive CandidiasisIndication
PneumocystisIndication
Mold InfectionIndication
Invasive Fungal DiseaseIndication
Recurrent Candidiasis of VaginaIndication
Cryptococcal MeningitisIndication
SepsisClinical trial
A Phase 1, Single-Center, Open-Label, 3-Cohort, Fixed-Sequence, Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 (DC-853) When Orally Administered Alone, When Coadministered With Itraconazole, Fluconazole, Or Carbamazepine In Healthy Adult ParticipantsStatus: Not yet recruiting, Estimated PCD: 2024-06-17
Clinical trial
A Phase 1, Open-Label, 4-Part, Fixed-Sequence Study to Assess the Effect of Itraconazole, a Strong CYP3A Inhibitor, the Effect of Fluconazole, a Moderate CYP3A/2C9 Inhibitor, the Effect of Rifampin, a Strong CYP3A Inducer, and the Effect of Rabeprazole, a Proton Pump Inhibitor on the Pharmacokinetics of HMPL-689 in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-08-06
Clinical trial
A Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole, and Carbamazepine in Healthy Adult ParticipantsStatus: Recruiting, Estimated PCD: 2024-05-06
Clinical trial
Drug-Drug Interaction Study of Multiple Doses of Pacritinib and CYP450 and, Transporter Substrates, and CYP450 3A4 Inducers and InhibitorsStatus: Completed, Estimated PCD: 2023-09-01
Clinical trial
Phase IIb/III Parallel-arm, Random., Active-controlled, Double-blind, Double-dummy, Multicenter, Non-inferiority Study in Patients With RVVC to Compare Efficacy, Safety and Tolerability of Topically Administered ProF-001 to Oral FluconazoleStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisStatus: Completed, Estimated PCD: 2021-10-07
Clinical trial
Randomized Controlled Trial to Assess the Effectiveness of a Zinc-containing Vaginal Gel and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis.Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
Pharmacokinetic Effect of Fluconazole on SHR2554 in Healthy Subjects in Single-center, Open-label, Single-dose, Auto-controlled PharmacokineticsStatus: Completed, Estimated PCD: 2023-03-31
Clinical trial
An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid TumorsStatus: Completed, Estimated PCD: 2019-10-31
Clinical trial
A Phase 1 Two-Part Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Fluconazole, and Between ALXN2050 and Rifampin in Healthy Adult ParticipantsStatus: Completed, Estimated PCD: 2021-08-04
Clinical trial
Single Dose Crossover Comparative Bioavailability Study of Fluconazole 200 mg Tablets Versus Diflucan® 200 mg Hard Capsules in Healthy Adult Subjects Under Fasting ConditionsStatus: Completed, Estimated PCD: 2019-09-17
Clinical trial
A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin Followed by Oral Ibrexafungerp Versus Intravenous Echinocandin Followed by Oral Fluconazole (MARIO)Status: , Estimated PCD: 2024-06-01
Clinical trial
A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell MalignanciesStatus: Completed, Estimated PCD: 2022-02-21
Clinical trial
PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
A Prospective, Randomized, Placebo-controlled Trial of Fluconazole in Combination With IL-23 Therapy Versus IL-23 Therapy Alone for the Treatment of Crohn's DiseaseStatus: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
Prospective Studies of Vaginal Yeast and Microbiome Related to Vulvovaginal Candidiasis in Canadian FemalesStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Endothelial Derived Hyperpolarization Factor and Regulation of Cerebral and Muscle Blood FlowStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D LevelsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized Controlled Trial: the Effect of a Medical Grade Honey Formulation (L-Mesitran) on Clinical Symptoms of Recurrent Vulvovaginal CandidiasisStatus: Recruiting, Estimated PCD: 2026-04-22
Clinical trial
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.Status: Completed, Estimated PCD: 2021-10-31
Clinical trial
Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ PersonsStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseStatus: Completed, Estimated PCD: 2018-12-01
Clinical trial
An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive CandidiasisStatus: Not yet recruiting, Estimated PCD: 2027-07-15
Clinical trial
A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic PatientsStatus: Withdrawn, Estimated PCD: 2008-12-01
Clinical trial
Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic AdultsStatus: Completed, Estimated PCD: 2016-06-01
Document
DailyMed Label: FluconazoleOrganization
Blenheim Pharmacal, Inc.Organization
Rebel Distributors Corp.Organization
A-S Medication SolutionsOrganization
NuCare Pharmaceuticals,Inc.Document
DailyMed Label: DiflucanOrganization
Roerig